Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care Poster Display session

236P - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience

Presentation Number
Lecture Time
12:45 - 12:45
  • Narges Sistany Allahabadi (Tehran, IR)
Hall A3 - Poster Area Networking Hub, ICM M√ľnchen, Munich, Germany
12:45 - 13:45



Sentinel lymph node dissection (SLND) after neoadjuvant chemotherapy (NAC) is of questionable accuracy. In this study we evaluated the feasibility and accuracy of SLND in breast cancer patients with clinically positive axillary nodes.


We conducted a prospective cross-sectional study on breast cancer patients diagnosed at Milad Hospital of Tehran, Iran from June 2014 to February 2015. Biopsy-proven node positive patients who converted to clinically node-negative following NAC and had a successful SLND (more than three identified SLNs) were included in the study. We used a 2 × 2 contingency table to analyze the feasibility of SLNB (sensitivity, specificity, false negative ratio, and accuracy). STATA statistical software (version 13.0, StataCorp LP, Texas, USA) was used for statistical analysis.


Among 52 patients who entered the study, 47 had a successful SLND (more than three identified SLNs) in whom we achieved a sensitivity of 100% (16/16), false-negative rate of 0% (0/21), a negative predictive value of 100% (16/16), and an overall accuracy of 89.4%.


SLND seems to be feasible and accurate in clinically lymph node positive breast cancer patients who achieve a clinically negative node status following neoadjuvant chemotherapy.

Legal entity responsible for the study

Iran University of Medical Sciences.


Milad General Hospital - Iran National Social Security Organization.


All authors have declared no conflicts of interest.